Welcome to our dedicated page for Traws Pharma news (Ticker: TRAW), a resource for investors and traders seeking the latest updates and insights on Traws Pharma stock.
Traws Pharma, Inc. (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company whose news flow centers on the development of investigational oral antivirals for major respiratory viral threats. Company announcements frequently highlight progress in its COVID-19 and influenza programs, including clinical trial milestones, interim data readouts, regulatory interactions and partnering activities.
A key focus of Traws’ news coverage is ratutrelvir, an investigational oral Mpro (3CL protease) inhibitor designed to treat SARS-CoV-2/COVID-19 without ritonavir. Recent press releases describe Phase 2 studies that compare ratutrelvir with PAXLOVID in patients with mild-to-moderate COVID-19 and evaluate its use in PAXLOVID-ineligible patients who face drug–drug interaction concerns with ritonavir-boosted regimens. Interim analyses reported by the company discuss patient-reported symptom outcomes, safety, tolerability and the presence or absence of viral or symptom rebound, as well as potential implications for Long COVID.
News items also cover tivoxavir marboxil (TXM), an investigational single-dose CAP-dependent endonuclease inhibitor for bird flu and seasonal influenza. Traws’ updates describe Phase 1 findings, preclinical results in multiple animal models using H5N1 virus, and interactions with agencies such as BARDA regarding potential inclusion of TXM in antiviral stockpiling initiatives for pandemic preparedness.
Investors following TRAW news can expect regular disclosures on quarterly financial results, business highlights, intellectual property and asset acquisitions, board and management changes, and corporate governance matters, as reflected in the company’s earnings releases and SEC filings. In addition, third-party announcements from collaborators, such as organizations providing chemistry, manufacturing and controls or AI-enabled predictive pharmacology support for ratutrelvir, may reference Traws’ clinical progress.
This news page aggregates these developments so readers can monitor how Traws’ clinical data, regulatory milestones and strategic decisions evolve over time. For those tracking antiviral pipelines for COVID-19, Long COVID, bird flu and seasonal influenza, the TRAW news feed offers a centralized view of the company’s publicly reported activities.
Traws Pharma (NASDAQ: TRAW) completed enrollment of a 90-patient Phase 2 open-label study of ratutrelvir versus PAXLOVID® and a single-arm cohort of PAXLOVID®-ineligible patients. Ongoing analyses report fewer adverse events, no viral rebounds to date, and faster time to sustained symptom resolution with ratutrelvir. Traws also advanced tivoxavir marboxil as a once-monthly oral influenza prophylactic; a compressed tablet is predicted to provide 28-day protection and a human challenge study is scheduled for June 2026.
Traws Pharma (NASDAQ: TRAW) filed a U.S. IND for tivoxavir marboxil (TXM) for oral influenza therapy and seeks BARDA consideration for strategic stockpile inclusion. The company also reported interim Phase 2 results for ratutrelvir, a ritonavir-free oral 3CL protease inhibitor, versus PAXLOVID® in mild-to-moderate COVID-19.
Key interim findings: ratutrelvir showed faster time-to-sustained symptom resolution (median 12 days vs 14 days, p<0.014), no observed viral rebounds versus one rebound in the PAXLOVID® arm, fewer adverse events (most common: mild dyspepsia in 7.6%), and applicability to PAXLOVID®-ineligible patients; study is ~95% enrolled with full enrollment expected in January 2026.
Traws Pharma (NASDAQ: TRAW) reported interim Phase 2 data (Dec 17, 2025) showing its oral, ritonavir‑free Mpro inhibitor ratutrelvir had a differentiated clinical profile versus PAXLOVID™ in 37 patients (25 ratutrelvir; 12 PAXLOVID™) in a randomized, open‑label study. Ratutrelvir was dosed 600 mg once daily for 10 days and showed numerically comparable time‑to‑sustained symptom alleviation, fewer adverse events (most common: mild dyspepsia in 2 patients; 7.6%), and no viral rebounds observed to date versus one rebound in the PAXLOVID™ arm (1 of 12; 8.3%). Six ratutrelvir patients were PAXLOVID‑ineligible and showed similar symptom improvement. Final analysis expected January 2026.
Traws Pharma (NASDAQ: TRAW) reported Q3 2025 results and program updates on Nov 13, 2025. The company expects topline Phase 2 data for ratutrelvir (ritonavir-free Mpro inhibitor) and a single-arm study in PAXLOVID-ineligible patients by year-end 2025. Traws initiated Phase 2 dosing and plans IND discussions for tivoxavir marboxil (TXM) for H5N1 and seasonal flu to support stockpiling. The company acquired intellectual property for a pyrrolidine antiviral for $2.6M, recording $2.6M intangible assets. Cash was $6.4M at Sept 30, 2025; Q3 net loss was $4.0M ($0.34/share).
Traws Pharma (NASDAQ: TRAW) advanced ratutrelvir into Phase 2 and secured extended CMC support from ChemDiv for API and drug product process research, scale-up, and analytical work. The first Phase 2 patient was dosed in October 2025 and top-line data are expected by year-end 2025. Ratutrelvir is a ritonavir-free Mpro (3CL) inhibitor developed by ChemDiv using Molsoft design and Expert Systems predictive pharmacology, designed for high potency across native and resistant SARS-CoV-2 strains and a 10-day, once-daily regimen.
Expert Systems is extending its contract to provide AI-enabled predictive safety pharmacology to support clinical progression and regulatory readiness.
Expert Systems Inc said it continues supporting Traws Pharma (NASDAQ: TRAW) as Traws begins Phase 2 trials of Ratutrelvir (TRX01), a ritonavir-free oral antiviral for newly diagnosed COVID-19 patients.
Key disclosed facts: Phase 1 MAD showed a 600 mg daily regimen sustaining plasma levels ~13× EC50 for a 10-day course with troughs above EC90. Regulatory clearance for Phase 2 was granted in Q3 2025. The Phase 2 program includes a non-inferiority trial vs PAXLOVID and a single-arm trial in PAXLOVID-ineligible patients. Expert Systems' AI-driven modeling contributed to PK and safety optimization and predicts higher lung tissue exposure.
Traws Pharma (NASDAQ: TRAW) announced dosing of the first subject in two Phase 2 studies of ratutrelvir, a ritonavir‑free oral antiviral for newly diagnosed COVID-19 patients on Oct 14, 2025.
One trial is a non-inferiority study versus PAXLOVID® assessing safety, disease rebound and incidence of Long COVID; a second is a single-arm study in PAXLOVID®‑ineligible patients. The company expects top-line data from both trials by year-end 2025. Management highlights once-daily, single‑tablet 10‑day dosing and aims to evaluate tolerability and rates of COVID symptoms and rebound.
Traws Pharma (NASDAQ: TRAW) appointed John Leaman, MD as an independent director effective October 1, 2025, and removed the "interim" title from Iain Dukes and Charles Parker, who are now CEO and CFO, respectively. The Board highlighted Leaman's finance, M&A and corporate‑strategy experience, including roles leading IPOs and Series D financing. Management said the company is preparing to enroll subjects in Phase 2 studies of ratutrelvir, a broadly acting oral COVID antiviral designed for use without ritonavir. The move was presented as strengthening governance and execution as Traws advances clinical development.
Traws Pharma (NASDAQ: TRAW) has received HREC approval to proceed with Phase 2 studies of ratutrelvir, their ritonavir-free COVID-19 treatment. The clinical program consists of two key trials: a non-inferiority study comparing ratutrelvir to PAXLOVID®, and a single-arm trial for PAXLOVID®-ineligible patients.
The trials will evaluate safety, efficacy, disease rebound rates, and Long COVID incidence, with top-line data expected by year-end 2025. The company highlights PAXLOVID®'s strong market presence, noting $427 million in Q2 2025 sales, a 70% year-over-year increase. Ratutrelvir's potential advantages include once-daily dosing, good tolerability, and broad activity against resistant strains.
Traws Pharma (NASDAQ: TRAW) reported Q2 2025 financial results and provided updates on its antiviral programs. The company ended Q2 with $13.1 million in cash, reporting revenue of $2.7 million and a net loss of $0.9 million ($0.11 per share).
Key developments include the prioritization of ratutrelvir, a ritonavir-free protease inhibitor for COVID-19 treatment, with Phase 2 studies planned to begin soon. The company is also advancing Tivoxavir Marboxil (TXM) for influenza, focusing on stockpiling readiness with BARDA.
Management changes include Jack Stover as new Board Chairman and Charles Parker as Interim CFO. The company will evaluate ratutrelvir versus PAXLOVID® in Phase 2 trials, with results expected by year-end 2025.
FAQ
What is the current stock price of Traws Pharma (TRAW)?
What is the market cap of Traws Pharma (TRAW)?
